Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.6K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.6K
Hybridoma Technology01:31

Hybridoma Technology

16.9K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
16.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.7K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The rapidly evolving BCMA landscape in multiple myeloma.

Blood·2026
Same author

Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients.

Blood cancer journal·2026
Same author

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN).

American journal of hematology·2026
Same author

Longitudinal mechanisms of response, resistance and relapse to teclistamab in multiple myeloma: results from MajesTEC-1.

Haematologica·2026
Same author

Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myeloma.

HemaSphere·2026
Same author

Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.

The New England journal of medicine·2026

Related Experiment Video

Updated: Dec 15, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.0K

Targeted Therapy With Immunoconjugates for Multiple Myeloma.

Wassilis S C Bruins1, Sonja Zweegman1, Tuna Mutis1

  • 1Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.

Frontiers in Immunology
|July 9, 2020
PubMed
Summary

New immunoconjugates offer hope for multiple myeloma (MM) patients refractory to standard therapies. These targeted treatments, like antibody-drug conjugates, show promise against resistant MM clones.

Keywords:
antibody-drug conjugatesimmunoconjugatesimmunocytokinesimmunotherapyimmunotoxinsmonoclonal antibodiesmultiple myelomaradioimmunoconjugates

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.5K
Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.9K

Related Experiment Videos

Last Updated: Dec 15, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.0K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.5K
Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.9K

Area of Science:

  • Hematology and Oncology
  • Immunotherapy
  • Drug Development

Background:

  • Proteasome inhibitors (PI), immunomodulatory drugs (IMiD), and monoclonal antibodies (mAb) have improved multiple myeloma (MM) survival.
  • Most MM patients eventually develop resistance to these therapies, necessitating novel treatment strategies.
  • Targeted immunotherapy, including unconjugated mAbs like daratumumab and elotuzumab, has shown significant clinical efficacy.

Purpose of the Study:

  • To review the mechanisms of action, safety, and efficacy of immunoconjugates for multiple myeloma (MM).
  • To discuss the potential of immunoconjugates in treating PI-, IMiD-, and mAb-refractory MM.
  • To explore future developments, including combination therapies and resistance mechanisms related to immunoconjugates.

Main Methods:

  • Review of preclinical and clinical studies on immunoconjugates in multiple myeloma (MM).
  • Classification of immunoconjugates based on effector moieties (e.g., antibody-drug conjugates, immunotoxins).
  • Analysis of targeted immunotherapy approaches utilizing antibody fragments as carriers for cytotoxic payloads.

Main Results:

  • Immunoconjugates, by fusing cytotoxic compounds to mAbs, offer distinct mechanisms of action against MM.
  • These targeted agents have the potential to overcome resistance in heavily pretreated MM patients.
  • Reduced off-target toxicity is achieved by conjugating potent effector moieties to mAbs, improving the therapeutic window.

Conclusions:

  • Immunoconjugates represent a promising therapeutic strategy for refractory multiple myeloma (MM).
  • Further investigation into their efficacy, safety, and combination potential is warranted.
  • Understanding resistance mechanisms will be crucial for optimizing immunoconjugate-based therapies in MM.